ES2103966T3 - Uso de una timosina en el tratamiento de hepatitis c. - Google Patents

Uso de una timosina en el tratamiento de hepatitis c.

Info

Publication number
ES2103966T3
ES2103966T3 ES92919977T ES92919977T ES2103966T3 ES 2103966 T3 ES2103966 T3 ES 2103966T3 ES 92919977 T ES92919977 T ES 92919977T ES 92919977 T ES92919977 T ES 92919977T ES 2103966 T3 ES2103966 T3 ES 2103966T3
Authority
ES
Spain
Prior art keywords
treatment
hepatitis
thymosine
thymosines
alone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92919977T
Other languages
English (en)
Spanish (es)
Inventor
Milton Mutchnick
Paul Chretian
Kenneth E Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Alpha 1 Biomedicals Inc
United States Department of the Army
Original Assignee
Wayne State University
Alpha 1 Biomedicals Inc
United States Department of the Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University, Alpha 1 Biomedicals Inc, United States Department of the Army filed Critical Wayne State University
Application granted granted Critical
Publication of ES2103966T3 publication Critical patent/ES2103966T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
ES92919977T 1991-09-13 1992-09-08 Uso de una timosina en el tratamiento de hepatitis c. Expired - Lifetime ES2103966T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13

Publications (1)

Publication Number Publication Date
ES2103966T3 true ES2103966T3 (es) 1997-10-01

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92919977T Expired - Lifetime ES2103966T3 (es) 1991-09-13 1992-09-08 Uso de una timosina en el tratamiento de hepatitis c.

Country Status (23)

Country Link
US (3) US6001799A (enExample)
EP (1) EP0603305B1 (enExample)
JP (1) JP3228512B2 (enExample)
KR (1) KR100254082B1 (enExample)
AT (1) ATE152914T1 (enExample)
AU (1) AU667327B2 (enExample)
CA (1) CA2119006C (enExample)
CZ (1) CZ286827B6 (enExample)
DE (1) DE69219782T2 (enExample)
DK (1) DK0603305T3 (enExample)
ES (1) ES2103966T3 (enExample)
FI (1) FI107879B (enExample)
GR (1) GR3024025T3 (enExample)
HK (1) HK1021687A1 (enExample)
HU (1) HU221006B1 (enExample)
MX (1) MX9205240A (enExample)
NO (1) NO941310L (enExample)
RO (1) RO111991B1 (enExample)
RU (1) RU2104010C1 (enExample)
SG (1) SG64897A1 (enExample)
TW (1) TW224053B (enExample)
WO (1) WO1993005806A1 (enExample)
ZA (1) ZA926964B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132037A1 (es) * 2006-05-10 2007-11-22 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien
SG64892A1 (en) * 1992-02-06 1999-05-25 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
EP0627930A4 (en) * 1992-07-13 1997-08-20 Kenneth E Sherman COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
DK0731710T3 (da) * 1993-11-05 2003-06-16 Sciclone Pharmaceuticals Inc Fremgangsmåde og præparat til behandling af patienter med inkompenseret leversygdom
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
AU722987B2 (en) * 1996-02-28 2000-08-17 Unihart Corporation Pharmaceutical compositions comprising natural human alpha-interferon
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
KR100851861B1 (ko) * 2000-08-07 2008-08-13 사이클론 파아머슈티컬 인코오퍼레이티드 티모신, 인터페론 및 리바비린을 사용한 씨 형 간염의치료
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
IL161022A0 (en) * 2001-10-05 2004-08-31 Intermune Inc Methods of treating liver fibrosis and hepatitis c virus infection
WO2003035010A2 (en) * 2001-10-26 2003-05-01 Rhode Island Hospital Thymosin augmentation of genetic immunization
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
JP2005522443A (ja) * 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
DK1613340T3 (da) 2003-03-28 2010-08-30 Sciclone Pharmaceuticals Inc Behandling af aspergillus-infektioner med thymosin alfa 1
PT1613340E (pt) * 2003-03-28 2010-08-19 Sciclone Pharmaceuticals Inc Tratamento de infecções por aspergillus com timosina alfa 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
ES2422290T3 (es) 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
RS52377B (sr) * 2006-05-02 2012-12-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Primena timozina 1, samog ili u kombinaciji sa ptx3 ili ganciklovirom, za lečenje infekcije citomegalovirusom
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20110195048A1 (en) * 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
TWI583692B (zh) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132037A1 (es) * 2006-05-10 2007-11-22 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas
ES2288118A1 (es) * 2006-05-10 2007-12-16 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.

Also Published As

Publication number Publication date
KR100254082B1 (ko) 2000-09-01
AU667327B2 (en) 1996-03-21
DK0603305T3 (da) 1997-09-01
HUT75166A (en) 1997-04-28
RU94022480A (ru) 1996-07-20
HU9400758D0 (en) 1994-06-28
FI941133L (fi) 1994-03-10
WO1993005806A1 (en) 1993-04-01
HU221006B1 (hu) 2002-07-29
DE69219782T2 (de) 1997-10-09
MX9205240A (es) 1993-07-01
DE69219782D1 (de) 1997-06-19
GR3024025T3 (en) 1997-10-31
RU2104010C1 (ru) 1998-02-10
US6001799A (en) 1999-12-14
SG64897A1 (en) 1999-05-25
AU2644792A (en) 1993-04-27
FI941133A0 (fi) 1994-03-10
EP0603305A1 (en) 1994-06-29
FI107879B (fi) 2001-10-31
CZ286827B6 (cs) 2000-07-12
HK1021687A1 (en) 2000-06-23
US5849696A (en) 1998-12-15
JP3228512B2 (ja) 2001-11-12
CA2119006A1 (en) 1993-04-01
TW224053B (enExample) 1994-05-21
ZA926964B (en) 1993-04-26
ATE152914T1 (de) 1997-05-15
CA2119006C (en) 2005-08-23
EP0603305B1 (en) 1997-05-14
JPH06510998A (ja) 1994-12-08
CZ55194A3 (en) 1994-10-19
NO941310D0 (no) 1994-04-12
US20070218033A1 (en) 2007-09-20
RO111991B1 (ro) 1997-04-30
NO941310L (no) 1994-04-12

Similar Documents

Publication Publication Date Title
ES2103966T3 (es) Uso de una timosina en el tratamiento de hepatitis c.
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
NO994091L (no) Medisinsk preparat inneholdende en lipofilisk inertgass
ES2186667T3 (es) Analogos de nucleosidos de 1,3-oxatiolano.
ES2188583T3 (es) Polipeptidos para el virus de la hepatitis c (hcv).
ES2143558T3 (es) Agentes policiclicos antiparasitarios, procedimiento y cepa para su preparacion y su uso.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
ES2182837T3 (es) Piran-2-onas y 5,6-dihidropiran-2-onas utiles en el tratamiento del sida y de otros retrovirus.
MX17808A (es) Nuevos derivados de artemisinina,procedimiento para su preparacion y su uso como agentes antiprosoos
BR9907882A (pt) Uso de compostos de 1,5-didesóxi-1,5-imino-d-glucitol n-substituìdos para o tratamento de infecções de vìrus de hepatite
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ES2108969T3 (es) Utilizacion de analogos de didesoxinucleosidos en el tratamiento de infecciones virales.
MX9706957A (es) Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina.
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
MX9304209A (es) Composicion y metodo de tratamiento de hepatitis b.
ES2120962T3 (es) Composicion antivirica.
NO890046L (no) Disubstituerte pyridiner.
TR199801289T2 (en) Terap�tik bile�ikler.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
ITMI912509A0 (it) Uso della nimesulide nel trattamento della cataratta
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 603305

Country of ref document: ES